GenScript Announces Collaboration with AMDeC: Seeks to Decrease Biological Research Costs at NYC Area Institutions
PISCATAWAY, N.J., Dec. 11, 2012 /PRNewswire/ — “GenScript has cemented an alliance with AMDeC, LLC, and is the first supplier to close a purchasing deal with AMDeC’s new Group Purchasing Organization (GPO) that is specifically targeting research products and services. AMDeC’s GPO allows Members, like NYU Langone Medical Center and Weill Cornell Medical College, to consolidate their purchasing power to obtain savings on products and services essential for life science research.”
GenScript is offering AMDeC members DNA sequencing services at deeply discounted prices. The services feature an easy, flexible sample submission and short turnaround times. But financial incentives aren’t the only motivation for this collaboration. DNA sequencing has been a catalyst for biological research since the 1970s. Access to fast, affordable sequencing has enabled researchers to sequence the first human genome, and study a variety of gene functions. Hence, the value of sequencing services to the research community has increased, as service turnaround times and prices have decreased. The GenScript-AMDeC collaboration provides scientists with rapid, economical, high-quality sequencing services, which will help accelerate research in the NYC area.
That’s just the tip of the iceberg for GenScript’s CEO, Frank Zhang, Ph.D., who anticipates that through this collaboration, GenScript will eventually offer its complete arsenal of one-stop custom services, including gene and peptide synthesis, protein expression and purification, antibody production, and cell line development. Access to these premier services would have the same catalytic effect as DNA sequencing has had over the years, since outsourcing these tasks expedites academic laboratory research.
“By working with AMDeC, we hope to establish services [at] every single university in the USA,” said Zhang. “Our vision is to make the research easy by providing custom reagents to scientists…[so that] the productivity in academic research labs will be improved.”
Both GenScript and AMDeC are committed to accelerating discoveries in biological research. Thus, it’s no coincidence that the potential for advancements in science and technology through this alliance is in parallel with AMDeC’s assertion as “A Catalyst for Breakthroughs” and GenScript’s core motto, “Transforming Biology Research”.
*Read more about the GenScript-AMDeC collaboration in the November 2012 issue of Nature Medicine.
GenScript is the leading gene, peptide, protein and antibody research partner for fundamental life science research, translational biomedical research, and early stage pharmaceutical development. Since our establishment in 2002, GenScript has exponentially grown to become a global leading biotech company that provides life sciences services and products to scientists over 100 countries worldwide. During our tenure we have built the best-in-class capacity and capability for biological research services encompassing gene synthesis and molecular biology, peptide synthesis, custom antibodies, protein expression, antibody and protein engineering, and in vitro and in vivo pharmacology – all with the goal to Make Research Easy.
AMDeC, LLC is a consortium of pre-eminent academic medical research institutions that promotes collaboration and efficient use of resources, with the goal of expediting discovery. AMDeC (www.amdecllc.com) is based in New York City.
# # # #
For further information, please contact:
Executive Vice President
Your Innovation Partner in Drug Discovery!